Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/ATelephone
61.3.9824.5254
Address
Level 3 62 Lygon Street Carlton, Victoria (VIC) 3053
Description
Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.03 - 0.15
Trade Value (12mth)
AU$10,646.00
1 week
-2.7%
1 month
-21.74%
YTD
-50.68%
1 year
-61.5%
All time high
0.45
EPS 3 yr Growth
N/A
EBITDA Margin
%
Operating Cashflow
-$23m
Free Cash Flow Return
-43.20%
ROIC
-64.50%
Interest Coverage
-429.70
Quick Ratio
1.20
Shares on Issue (Fully Dilluted)
343m
HALO Sector
Healthcare
Next Company Report Date
26-Sep-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
23 July 24 |
FDA IND approval for Phase 2b trial in brain metastases
×
FDA IND approval for Phase 2b trial in brain metastases |
17 July 24 |
Correction to Notice of Extraordinary General Meeting
×
Correction to Notice of Extraordinary General Meeting |
16 July 24 |
Notice of Extraordinary General Meeting/Proxy Form
×
Notice of Extraordinary General Meeting/Proxy Form |
10 July 24 |
First patient dosed in Phase 1 therapeutic lung cancer trial
×
First patient dosed in Phase 1 therapeutic lung cancer trial |
08 July 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
05 July 24 |
Change in substantial holding PH
×
Change in substantial holding PH |
03 July 24 |
GN20 Disclosure
×
GN20 Disclosure |
03 July 24 |
Becoming a substantial holder
×
Becoming a substantial holder |
03 July 24 |
Becoming a substantial holder
×
Becoming a substantial holder |
02 July 24 |
RAD notifies end of share agreements with Lind Partners
×
RAD notifies end of share agreements with Lind Partners |
02 July 24 |
Notice Under Section 708A
×
Notice Under Section 708A |
01 July 24 |
Application for quotation of securities - RAD
×
Application for quotation of securities - RAD |
27 June 24 |
Investor webinar 3pm AEST Tuesday 2 July
×
Investor webinar 3pm AEST Tuesday 2 July |
25 June 24 |
Radiopharm Theranostics completes A$70 million placement
×
Radiopharm Theranostics completes A$70 million placement |
25 June 24 |
Lantheus Strategic Investment and Capital Raise Presentation
×
Lantheus Strategic Investment and Capital Raise Presentation |
25 June 24 |
Proposed issue of securities - RAD
×
Proposed issue of securities - RAD |
25 June 24 |
Proposed issue of securities - RAD
×
Proposed issue of securities - RAD |
25 June 24 |
Reinstatement to Quotation
×
Reinstatement to Quotation |
24 June 24 |
Suspension from Quotation
×
Suspension from Quotation |
20 June 24 |
Trading Halt
×
Trading Halt |
20 June 24 |
Radiopharm Receives Strategic Investment for up to A$18 mill
×
Radiopharm Receives Strategic Investment for up to A$18 mill |
20 June 24 |
Proposed issue of securities - RAD
×
Proposed issue of securities - RAD |
23 May 24 |
Change in substantial holding PH
×
Change in substantial holding PH |
23 May 24 |
Change in substantial holding NanoMab
×
Change in substantial holding NanoMab |
16 May 24 |
Application for quotation of securities - RAD
×
Application for quotation of securities - RAD |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.